Keywords: آلک; Mucoepidermoid carcinoma; Adenocarcinoma; Mixed lung cancer; EGFR; ALK; Driver mutation;
مقالات ISI آلک (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: آلک; Non-small cell lung cancer; Squamous cell carcinoma; Smoking; EGFR; PIK3CA; ALK;
Keywords: آلک; Non-small-cell lung cancer; Next generation sequencing; Genotype; EGFR; ALK; Driver oncogene; MET; ROS1; MET; Adenocarcinoma; Squamous cell carcinomas;
Keywords: آلک; ACTH; adrenocorticotropin; ACTH-R; adrenocorticotropin receptor; ActRI; activin type-I receptor; ActRII; activin type-II receptor; ALK; activin receptor-like kinase; AngII; angiotensin II; AT1R; Ang II type 1 receptor; BMP; bone morphogenetic protein; BMP
Keywords: آلک; ABK; aphakic bullous keratopathy; ALK; anterior lamellar keratoplasty; DALK; deep anterior lamellar keratoplasty; DMEK; Descemet membrane endothelial keratoplasty; DSAEK; Descemet stripping automated endothelial keratoplasty; DSEK; Descemet stripping endo
Keywords: آلک; Biomarkers; Lung cancer; NSCLC; EGFR; ALK; ROS1; RET
Keywords: آلک; Tyrosine kinase inhibitor; NSCLC; Cranial radiotherapy; Neurotoxicity; EGFR; ALK
Keywords: آلک; Soft tissue pathology; Sarcoma; Molecular; Liposarcoma; ALK
Keywords: آلک; Seminal fluid; Cervical epithelial cells; Cytokines; Inflammation; ALK; activin-like kinase; BMP; bone morphogenetic protein; BSA; bovine serum albumin; CSF2; colony stimulating factor-2; CCL; chemokine (C-C motif) ligand; DMEM; Dulbecco's minimal essen
Keywords: آلک; 4-HPR; N-(4-hydroxyphenyl)retinamide; 5â²-UTR; 5â²-untranslated region; 9-cis-RA; 9-cis retinoic acid; 9cUAB30; (2E,4E,6Z,8E)-8-(3â²,4â²-dihydro-1â²(2'H)-naphthalen-1â²-ylidene)-3,7-dimethyl-2,4,6-octatrienoic acid; Acitretin; (2E,4E,6E,8E)-9-(4-met
Keywords: آلک; Inflammatory pseudotumor; Head and neck; IgG4; ALK;
Keywords: آلک; Crizotinib; Renal insufficiency; Lung adenocarcinoma; Tyrosine kinase inhibitors; ALK; Toxicity
Keywords: آلک; Inflammatory myofibroblastic tumor; ALK; Mesentery; Immunohistochemistry; Pediatric
Keywords: آلک; Lung cancer; Non-small-cell lung cancer; Never smokers; Epidermal growth factor receptor; EGFR; Anaplastic lymphoma kinase; ALK; KRAS; Tumor genotype; Failure; Bone specimen; Core biopsy; Molecular testing;
Keywords: آلک; Lung cancer; Biomarker; Molecular diagnostics; EGFR; Alk; NGS
Keywords: آلک; EGFR; epidermal growth factor receptor (EGFR); ErbB; epidermal growth factor receptor family (ErbB); PI3K; phosphatidylinositol 3-kinase (PI3K); AKT; protein kinase B; mTOR; mammalian target of rapamycin; VEGF; vascular endothelial growth factor; ALK; ana
Keywords: آلک; Growth factors; Interaction; Proliferation; Migration; Protect and label; a.a.; amino acid; ALK; anaplastic lymphoma kinase; ASP; aspartic acid; CTGF; connective tissue growth factor; FGF-2; fibroblast growth factor-2; GLU; glutamic acid; HARP; heparin af
Keywords: آلک; KRAS; Lung; Young; Molecular; EGFR; ALK; BRAF; Non-small cell lung carcinoma; Fine needle aspiration
Keywords: آلک; ALK; anaplastic lymphoma kinase; EGFR; epidermal growth factor receptor; FGFR; fibroblast growth factor receptor; FISH; fluorescence in situ hybridization; MET; mesenchymal epithelial transition; NGS; next-generation sequencing; SQCC; squamous cell carcin
Keywords: آلک; Lung cytology; Immunohistochemistry; Molecular testing; EGFR; ALK
Keywords: آلک; Decorin; Lumican; Fibromodulin; Toll-like receptor; Matrix metalloproteinases; 5/6-Nx; 5/6-nephrectomized Sprague-Dawley rats; ADAMTS; a disintegrin and metalloproteinase with thrombospondin motifs; ALK; activin like kinase; ATS; hymocyte serum; BGN (Bgn)
Keywords: آلک; VEGF(R); vascular endothelial growth factor (receptor); EGF(R); epidermal growth factor (receptor); LGG; low-grade glioma; HGG; high-grade glioma; DIPG; diffuse intrinsic pontine glioma; PDGF(R); platelet derived growth factor (receptor); P(I)GF; placenta
Keywords: آلک; VEGF; vascular endothelial growth factor; PTN; pleiotrophin; ALK; N-syndecan anaplastic lymphoma kinase; RPTPβ/ζ; receptor protein tyrosine phosphatase β/ζ; Senescence; Angiogenesis; Vascular endothelial growth factor; Isolated aortic rings; Heparin b
Keywords: آلک; ALK; EML4; Oesophageal cancer; Translocation; Amplification; STAT3;
Keywords: آلک; Lung cancer; Non-small-cell lung cancer; Never smokers; Epidermal growth factor receptor; EGFR; Anaplastic lymphoma kinase; ALK; KRAS;
Keywords: آلک; WAT; white adipose tissue; BAT; brown adipose tissue; MSC; mesenchymal stem cell; UCP1; uncoupling protein 1; PRDM16; PR domain containing 16; PPARγ; peroxisome proliferator-activated receptor gamma; BMP; bone morphogenic protein; PGC1; peroxisome prolif
Keywords: آلک; ALDHhi; high expression of aldehyde dehydrogenase; ALK; activin-like kinase receptor; AP; anterior-posterior; AVE; anterior visceral endoderm; BMPs; bone morphogenic proteins; CER1; Cerberus; CFC; conserved cysteine-rich domain; CSCs; cancer stem cells;
Keywords: آلک; Lung; Pulmonary; Adenocarcinoma; ALK; ROS1; Pediatric patients
Neoadjuvant crizotinib in ALK-rearranged inflammatory myofibroblastic tumor of the urinary bladder: A case report
Keywords: آلک; Inflammatory myofibroblastic tumor; Urinary bladder; ALK; Crizotinib;
Bioanalytical assay for the quantification of the ALK inhibitor lorlatinib in mouse plasma using liquid chromatography-tandem mass spectrometry
Keywords: آلک; ALK; anaplastic lymphoma kinase; EMA; European Medicines Agency; EML4; echinoderm microtubule-associated protein-like 4; ESI; electro spray ionization; FDA; Food and Drug Administration; IS; internal standard; LC-MS/MS; liquid chromatography-tandem mass s
Impact of a comprehensive geriatric assessment to manage elderly patients with locally advanced non-small-cell lung cancers: An open phase II study using concurrent cisplatin-oral vinorelbine and radiotherapy (GFPC 08-06)
Keywords: آلک; ALK; anaplastic lymphoma kinase gene; CGA; comprehensive geriatric assessment; CT; computed-tomography scan; EGFR; epidermal growth-factor; ECOG PS; Eastern Cooperative Oncology Group performance status; La-NSCLC; locally advanced non-small-cell lung ca
Assessment of EGFR mutation status in Tunisian patients with pulmonary adenocarcinoma
Keywords: آلک; EGFR; ALK; Non-small cell lung cancer; Adenocarcinoma; Real-time polymerase chain reaction;
Identification of NMU as a potential gene conferring alectinib resistance in non-small cell lung cancer based on bioinformatics analyses
Keywords: آلک; NSCLC; non-small cell lung cancer; ALK; anaplastic lymphoma kinase; GEO; gene expression omnibus; DEGs; differentially expressed genes; DAVID; database for annotation, visualization and integrated discovery; GO; gene ontology; KEGG; kyoto encyclopedia of
Biopsie liquide et cibles thérapeutiques, enjeux actuels et futurs en oncologie thoracique
Keywords: آلک; ALK; biopsie liquid; cancer pulmonaire; EGFR; médecine stratifiée; ALK; EGFR; liquid biopsy; lung cancer; stratified medicine;
Tumor biomarker testing in non-small-cell lung cancer: A decade of change
Keywords: آلک; Lung cancer; Adenocarcinoma; Biomarker testing; Smoking history; EGFR; ALK;
Efficacy and safety of nivolumab in previously treated patients with non-small cell lung cancer: A multicenter retrospective cohort study
Keywords: آلک; AE; adverse event; ALK; anaplastic lymphoma kinase; CR; complete response; DCR; disease control rate; ECOG PS; Eastern Cooperative Oncology Group Performance Status; EGFR; epidermal growth factor receptor; HR; hazard ratio; irAE; immune related adverse ev
Phase II study of tailored S-1 monotherapy with a 1-week interval after a 2-week dosing period in elderly patients with advanced non-small cell lung cancer
Keywords: آلک; ALK; anaplastic lymphoma kinase; ALT; alanine aminotransferase; AST; aspartate aminotransferase; BSA; body surface area; Ccr; creatinine clearance; CI; confidence interval; CR; complete response; CTCAE; common terminology criteria for adverse events; DCR;
ALK is required for NLRP3 inflammasome activation in macrophages
Keywords: آلک; ALK; Macrophage; Inflammasome; NF-κB; Lipid peroxidation; PAMP; pathogen-associated molecular pattern molecule; DAMP; damage-associated molecular pattern molecule; NLRP3; NLR family pyrin domain containing; PYCARD; PYD and CARD doma0069n containing; ATP;
Interaction between orexin A and bone morphogenetic protein system on progesterone biosynthesis by rat granulosa cells
Keywords: آلک; AC; adenylate cyclase; ALK; activin receptor-like kinase; ActRII; activin type-II receptor; BMP; bone morphogenetic protein; BMPRII; BMP type-II receptor; DOR; dorsomorphin; FSH; follicle-stimulating hormone; FSHR; FSH receptor; GDF; growth and differenti
Factors associated with gene aberration test status and treatment decision in patients with unresectable Stage IIIB/IV nonsquamous non-small cell lung cancer: A multicenter survey in China (CTONG 1506)
Keywords: آلک; ALK; anaplastic lymphoma kinase; CI; confidence interval; CTONG; Chinese Thoracic Oncology Group; ECOG; Eastern Cooperative Oncology Group; EGFR; epidermal growth factor receptor; MERAF; Medical Record Abstraction Form; NSCLC; non-small cell lung cancer;
Prevalence of ALK gene alterations among the spectrum of plexiform spitzoid lesions
Keywords: آلک; ALK; atypical Spitz tumor; plexiform melanocytic lesions; AST; atypical Spitz tumor; FFPE; formalin-fixed, paraffin-embedded; FISH; fluorescence in situ hybridization; IHC; immunohistochemistry; RT-PCR; reverse-transcriptase polymerase chain reaction; SM;
Rare targetable drivers (RTDs) in non-small cell lung cancer (NSCLC): Outcomes with immune check-point inhibitors (ICPi)
Keywords: آلک; ALK; anaplastic lymphoma kinase; BRAF; v-Raf murine sarcoma viral oncogene homolog B; cMET; tyrosine-protein kinase Met/hepatocyte growth factor receptor; CT; computer tomography; ECOG; PS Eastern Cooperative Oncology Group performance status; EGFR; epide
Radiogenomics and IR
Keywords: آلک; ALK; anaplastic lymphoma kinase; BAP1; BRCA1-associated protein 1; EGFR; epidermal growth factor receptor; HCC; hepatocellular carcinoma; HIF1a; hypoxia-inducible factor-1-alpha; KDM5C; lysine-specific demethylase 5C; KRAS; Kirsten rat sarcoma viral oncog
Brigatinib in Patients With Alectinib-Refractory ALK-Positive NSCLC
Keywords: آلک; Alectinib; Brigatinib; ALK; NSCLC; Resistance;
Ventana ALK (D5F3) in the Detection of Patients Affected by Anaplastic Lymphoma Kinase-positive Non-Small-cell Lung Cancer: Clinical and Budget Effect
Keywords: آلک; ALK; Budget; FISH; IHC; NSCLC;
Nivolumab in advanced non-small-cell lung cancer patients who failed prior platinum-based chemotherapy
Keywords: آلک; AE; adverse event; ALK; anaplastic lymphoma kinase; ALT; alanine aminotransferase; AST; aspartate aminotransferase; CI; confidence interval; CR; complete response; ECOG; Eastern Cooperative Oncology Group; EGFR; epidermal growth factor receptor; HR; hazar
Heterobicyclic inhibitors of transforming growth factor beta receptor I (TGFβRI)
Keywords: آلک; TGF; TGF-beta; TGFβ; ALK; TGFBR;
Fatal acute disseminated intravascular coagulation as presentation of advanced ALK-positive non-small cell lung cancer: Does oncogene addiction matter?
Keywords: آلک; NSCLC; ALK; Thrombosis; DIC;
Thermophilic anaerobic digestion of pre-treated orange peel: Modelling of methane production
Keywords: آلک; Alk; alkalinity (mg CaCO3/L); b; model parameter of Logistic Gompertz and Sigmoid models; C2; acetic acid with two carbon atoms; COD; chemical oxygen demand (mgâO2/g, g COD/L, g COD/g VSSâd, g COD); CSTR; continuously stirred-tank reactor; G; meth
Root bark extracts of Myrianthus arboreus P. Beauv. (Cecropiaceae) exhibit anti-diabetic potential by modulating hepatocyte glucose homeostasis
Keywords: آلک; AMPK; AMP-activated protein kinase; Alk; alkaloid extract; AQ; aqueous fraction; CREB; c-AMP-regulator element-binding protein; Dic; dicloromethane extract; EtOH; ethanol extract; G6Pase; glucose-6-Phosphatase; GS; glycogen Synthase; GSK-3; glycogen Synth